A distinct plasma lipid signature associated with poor prognosis in castration‐resistant prostate cancer
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Lipids are known to influence tumour growth, inflammation and chemoresistance. However, the association of circulating lipids with the clinical outcome of metastatic castration‐resistant prostate cancer (CRPC) is unknown. We investigated associations between the plasma lipidome and clinical outcome in CRPC. Lipidomic profiling by liquid chromatography‐tandem mass spectrometry was performed on plasma samples from a Phase 1 discovery cohort of 96 CRPC patients. Results were validated in an independent Phase 2 cohort of 63 CRPC patients. Unsupervised analysis of lipidomic profiles (323 lipid species) classified the Phase 1 cohort into two patient subgroups with significant survival differences (HR 2.31, 95% CI 1.44–3.68, p = 0.0005). The levels of 46 lipids were individually prognostic and were predominantly sphingolipids with higher levels associated with poor prognosis. A prognostic three‐lipid signature was derived (ceramide d18:1/24:1, sphingomyelin d18:2/16:0, phosphatidylcholine 16:0/16:0) and was also associated with shorter survival in the Phase 2 cohort (HR 4.8, 95% CI 2.06–11.1, p = 0.0003). The signature was an independent prognostic factor when modelled with clinicopathological factors or metabolic characteristics. The association of plasma lipids with CRPC prognosis suggests a possible role of these lipids in disease progression. Further research is required to determine if therapeutic modulation of the levels of these lipids by targeting their metabolic pathways may improve patient outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis
Menendez, J. A., & Lupu, R. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2222 · Cited by 2,941 · cited 1×
“Lipids contribute to cancer growth as energy substrates, cell membrane constituents and signalling molecules in the regulation of cell cycle, apoptosis, angiogenesis and inflammation.(4,5) Lipids may also influence chemoresponse, where a higher degree of lipid saturation in membranes was shown to promote the chemoresi…”
BackgroundMeikle, P. J., Wong, G., Tan, R., Giral, P., Robillard, P., Orsoni, A., Hounslow, N., Magliano, D. J., Shaw, J. E., Curran, J. E., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.p061143 · Cited by 65
Self-citationEffect of pioglitazone on plasma ceramides in adults with metabolic syndrome
Warshauer, J. T., Lopez, X., Gordillo, R., Hicks, J., Holland, W. L., Anuwe, E., Blankfard, M. B., Scherer, P. E., & Lingvay, I. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2662 · Cited by 51
Cited by
Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention
Butler, L. M., Perone, Y., Dehairs, J., Lupien, L. E., de Laat, V., Talebi, A., Loda, M., Kinlaw, W. B., & Swinnen, J. V. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.013 · Cited by 589
Tumour fatty acid metabolism in the context of therapy resistance and obesity
Hoy, A. J., Nagarajan, S. R., & Butler, L. M. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00388-4 · Cited by 392
Self-citationPhospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets
Kopecka, J., Trouillas, P., Gašparović, A. Č., Gazzano, E., Assaraf, Y. G., & Riganti, C. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100670 · Cited by 291
Extracellular Fatty Acids Are the Major Contributor to Lipid Synthesis in Prostate Cancer
Balaban, S., Nassar, Z. D., Zhang, A. Y., Hosseini-Beheshti, E., Centenera, M. M., Schreuder, M., Lin, H.-M., Aishah, A., Varney, B., Liu-Fu, F., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0347 · Cited by 82
Self-citationLipid profiles of prostate cancer cells
Sorvina, A., Bader, C. A., Caporale, C., Carter, E. A., Johnson, I. R. D., Parkinson-Lawrence, E. J., Simpson, P. V., Wright, P. J., Stagni, S., Lay, P. A., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26222 · Cited by 44
Metadata
- Authors
- Lin, H., Mahon, K. L., Weir, J. M., Mundra, P. A., Spielman, C., Briscoe, K., Gurney, H., Mallesara, G., Marx, G., Stockler, M. R., PRIMe Consortium, Parton, R. G., Hoy, A. J., Daly, R. J., Meikle, P. J., & Horvath, L. G.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2017-08-08
- Volume
- 141
- Issue
- 10
- Pages
- 2112-2120
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2738428060
- Cited by
- 83
- References
- 3
- FWCI
- 1.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A distinct plasma lipid signature associated with poor prognosis in castration‐resistant prostate cancer. https://app.cochat.ai/papers/10.1002/ijc.30903
- The paper
- Lin, H., Mahon, K. L., Weir, J. M., Mundra, P. A., Spielman, C., Briscoe, K., Gurney, H., Mallesara, G., Marx, G., Stockler, M. R., PRIMe Consortium, Parton, R. G., Hoy, A. J., Daly, R. J., Meikle, P. J., & Horvath, L. G. (2017). A distinct plasma lipid signature associated with poor prognosis in castration‐resistant prostate cancer. International Journal of Cancer. https://doi.org/10.1002/ijc.30903
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.